產(chǎn)品中心
PRODUCT CENTER
首寧生物hiPSC/hESC高效凍存液是一款化學(xué)成分明確,無血清配方,且無動(dòng)物源成分的即用型臨床級(jí)/藥品級(jí)凍存保護(hù)液。保證細(xì)胞未分化狀態(tài)和擴(kuò)增能力的同時(shí),大大降低了凍存過程中冰晶對細(xì)胞的損傷,有效提高細(xì)胞復(fù)蘇效率和活率。
說明書下載
(1)無血清、無動(dòng)物源成分、化學(xué)成分明確;
(2)自主化、國產(chǎn)化的原研體系;供貨穩(wěn)定,高性價(jià)比;
(3)支持臨床級(jí)/藥品級(jí)細(xì)胞培養(yǎng),培養(yǎng)的iPSC細(xì)胞通過了中國食品藥品檢定研究院質(zhì)量復(fù)核;iPSC來源功能藥物通過了IND默示許可。
產(chǎn)品 | 規(guī)格 | 貨號(hào) | 存儲(chǔ)條件 |
hiPSC/hESC高效凍存 | 50mL | RP01003 | -2℃~8℃ |
hiPSC/hESC高效凍存液保存的hiPSC(P13)復(fù)蘇后細(xì)胞形態(tài)圖示。
圖示分別為細(xì)胞復(fù)蘇第1、2、3天時(shí),顯微鏡下hiPSC的形態(tài)圖示。標(biāo)尺:200μm。
Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val
2020. He Shan, et al. Stem Cell Research(IF 1.587).
Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation
2020. He Shan , et al. Stem Cell Research(IF 1.587).
Generation of an induced pluripotent stem cell (iPSC) line (THSJTUi001-A) from a Wilson's disease patient harboring a homozygous Arg778Leu mutation in ATP7B gene
2020. Wang, Shu Hong , et al. Stem Cell Research(IF 1.587).
更多文獻(xiàn)引用,請撥打021-61283010詳細(xì)咨詢